Ofost (Oxytocin)

Oxytocin binds to oxytocin receptors on uterine smooth muscle, activating phospholipase C and increasing intracellular calcium, which triggers coordinated muscle contractions. The same receptor activation in the mammary glands stimulates milk ejection. This mechanism underlies its clinical use in labor and postpartum management.

The specific dose of Ofost is determined by the prescribing clinician based on the indication, patient condition, and response. Dosing regimens are individualized and may involve an initial bolus followed by a controlled infusion, with careful monitoring of uterine activity and fetal status.

Oxytocin is classified as Pregnancy Category B, indicating no evidence of risk in human studies, and it is routinely used during pregnancy for labor management. It is also considered compatible with breastfeeding, as it is naturally produced in the body and does not accumulate in breast milk.

To order Ofost, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Ofost contains oxytocin, the standard oxytocic agent, and its efficacy and safety profile are comparable to other oxytocin products on the market. Alternatives such as prostaglandin analogues have different mechanisms and may be used when oxytocin is contraindicated, but oxytocin remains the first‑line choice for most labor‑related indications.

Ofost should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Ofost is supplied as a sterile injectable solution for intramuscular or intravenous administration. It is typically given by a qualified health professional using aseptic technique, either as a single bolus dose or as a controlled infusion, with continuous monitoring of uterine activity and maternal‑fetal status.

The most serious risks include uterine hyperstimulation leading to fetal distress, uterine rupture, water intoxication from excessive fluid retention, and rare allergic reactions such as anaphylaxis. Continuous monitoring of uterine tone, fetal heart rate, and fluid balance is essential to mitigate these risks.

Ofost should be avoided in patients with known hypersensitivity to oxytocin, in cases of severe uncontrolled hypertension, in women with a history of uterine rupture or major uterine surgery where further contraction poses risk, and in fetuses with known distress where increased uterine activity could be harmful.